Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Antineoplastic Combined Chemotherapy Protocols
Platinum
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Drug Resistance, Neoplasm
Drug Administration Schedule
Etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Ovarian Neoplasms
Combined Modality Therapy
DNA Adducts
Fluorouracil
Paclitaxel
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Ifosfamide
Treatment Outcome
Carcinoma, Squamous Cell
Drug Screening Assays, Antitumor
Carcinoma, Non-Small-Cell Lung
Survival Analysis
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Doxorubicin
Taxoids
Infusions, Intravenous
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Dose-Response Relationship, Drug
Disease-Free Survival
Tumor Cells, Cultured
Testicular Neoplasms
Nausea
Mitomycin
Survival Rate
Camptothecin
Neoplasm Staging
Vindesine
Cell Survival
DNA Damage
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Carcinoma, Small Cell
Bleomycin
Tegafur
Neoplasms, Germ Cell and Embryonal
Antineoplastic Agents, Phytogenic
DNA Repair
The reconstruction of a continuous two-stranded DNA molecule without mismatch from a molecule which contained damaged regions. The major repair mechanisms are excision repair, in which defective regions in one strand are excised and resynthesized using the complementary base pairing information in the intact strand; photoreactivation repair, in which the lethal and mutagenic effects of ultraviolet light are eliminated; and post-replication repair, in which the primary lesions are not repaired, but the gaps in one daughter duplex are filled in by incorporation of portions of the other (undamaged) daughter duplex. Excision repair and post-replication repair are sometimes referred to as "dark repair" because they do not require light.
Germinoma
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Drug Evaluation
Neoplasm Recurrence, Local
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
Chemotherapy, Adjuvant
Neoplasms
Maximum Tolerated Dose
Epirubicin
Pleural Neoplasms
Ondansetron
Mice, Nude
Amifostine
Carcinoma
Tumor Suppressor Protein p53
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Radiation-Sensitizing Agents
Induction Chemotherapy
Neoadjuvant Therapy
Osteosarcoma
Remission Induction
Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/7975)
Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients. (+info)Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/7975)
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. (+info)Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. (3/7975)
Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise. (+info)MycN sensitizes neuroblastoma cells for drug-induced apoptosis. (4/7975)
Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-X(L) protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited. (+info)A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. (5/7975)
Multinuclear platinum compounds have been designed to circumvent the cellular resistance to conventional platinum-based drugs. In an attempt to examine the cellular basis of the preclinical antitumor efficacy of a novel multinuclear platinum compound (BBR 3464) in the treatment of cisplatin-resistant tumors, we have performed a comparative study of cisplatin and BBR 3464 in a human osteosarcoma cell line (U2-OS) and in an in vitro selected cisplatin-resistant subline (U2-OS/Pt). A marked increase of cytotoxic potency of BBR 3464 in comparison with cisplatin in U2-OS cells and a complete lack of cross-resistance in U2-OS/Pt cells were found. A detailed analysis of the cisplatin-resistant phenotype indicated that it was associated with reduced cisplatin accumulation, reduced interstrand cross-link (ICL) formation and DNA platination, microsatellite instability, and reduced expression of the DNA mismatch repair protein PMS2. Despite BBR 3464 charge and molecular size, in U2-OS and U2-OS/Pt cells, BBR 3464 accumulation and DNA-bound platinum were much higher than those observed for cisplatin. In contrast, the frequency of ICLs after exposure to BBR 3464 was very low. The time course of ICL formation after drug removal revealed a low persistence of these types of DNA lesions induced by BBR 3464, in contrast to an increase of DNA lesions induced by cisplatin, suggesting that components of the DNA repair pathway handle the two types of DNA lesions differently. The cellular response of HCT116 mismatch repair-deficient cells was consistent with a lack of influence of mismatch repair status on BBR 3464 cytotoxicity. Because BBR 3464 produces high levels of lesions different from ICLs, likely including intra-strand cross-links and monoadducts, the ability of the triplatinum complex to overcome cisplatin resistance appears to be related to a different mechanism of DNA interaction (formation of different types of drug-induced DNA lesions) as compared with conventional mononuclear complexes rather than the ability to overcome specific cellular alterations. (+info)Testicular cancer: an oncological success story. (6/7975)
Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short-duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors. (+info)Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. (7/7975)
To determine the effectiveness of non-cross-resistant late-consolidation chemotherapy in locally advanced breast cancer (LABC) and stage IV breast cancer, we review our experience with two regimens. Between 1985 and 1991, we enrolled 56 patients with LABC, who were treated with a doxorubicin-based adjuvant regimen, followed by a late-consolidation non-cross-resistant regimen containing methotrexate, 5-fluorouracil, cisplatin, and cyclophosphamide. Between 1985 and 1996, a total of 45 patients with limited stage IV breast cancer underwent surgical excision of all evaluable disease, making them metastatic (stage IV) with no evaluable disease. Surgery was followed by a doxorubicin-containing regimen and then a late-consolidation non-cross-resistant regimen, which was either methotrexate, 5-fluorouracil, cisplatinum, and cyclophosphamide or 5-fluorouracil, mitomycin, etoposide, and cisplatin. Twenty-four patients with limited bone metastases that were unresectable were treated with a doxorubicin-containing regimen, radiation therapy to all sites of disease, and then one of the two late non-cross-resistant regimens. With a median follow-up of 84 months, 78% of patients with LABC are alive, and 68% are free of disease. After a median follow-up of 44 months, 53% of patients with stage IV with no evaluable disease are alive and free of disease. The use of non-cross-resistant late-consolidation chemotherapy is an effective strategy in the treatment of patients with LABC and selected patients with limited stage IV breast cancer. (+info)Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. (8/7975)
The induction of collateral radioresistance after the development of cisplatin resistance is a well-documented phenomenon; however, the exact processes that are responsible for the cisplatin-induced radioresistance remain to be elucidated. There was no obvious difference in the level of radiation-induced DNA double strand breaks (DSBs), in DSB rejoining rates, or the level of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) in the cisplatin- and radiation-sensitive 2780/WT and cisplatin-resistant 2780/CP cell lines. However, there was a significantly (P < 0.01) lower level of DSB misrejoining activity within nuclear protein extracts derived from the cisplatin- and radiation-sensitive 2780/WT and OAW42/WT tumour cell lines than in similar extracts from their cisplatin- (and radiation-) resistant 2780/CP and OAW42/CP counterparts. All of the DSB misrejoining events involved deletions of between 134 and 444 bp that arose through illegitimate recombination at short repetitive sequences, such as those that arise through non-homologous repair (NHR). These data further support the notion that the radiosensitivity of DSB repair proficient human tumour cell lines may be partly determined by the predisposition of these cell lines to activate non-conservative DSB rejoining pathways. Furthermore, our data suggest that the induction of acquired cisplatin resistance is associated with a two- to threefold decrease in the activity of a non-conservative DSB rejoining mechanism that appears to be a manifestation of NHR. (+info)O<sup>6</sup>-methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts...
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines | Journal of Ovarian Research |...
Raman spectroscopy: A novel experimental approach to evaluating cisplatin induced tissue damage | AVESİS
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation
Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell...
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer | BMC Cancer |...
The effects of the antioxidant α-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells<...
Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest | Butaren
Dexamethasone for the Prevention of Cisplatin-induced Ototoxicity - Kent Academic Repository
Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer |...
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer...
Molecular basis for resistance to the anticancer drug cisplatin in DictyosteliumThe GenBank accession numbers for the sequences...
The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells<...
Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatin−DNA Interstrand Cross-Links
erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic...
Induktion und Reparatur von DNA-Doppelstrangbrüchen nach kombinierter Einwirkung von Cisplatin und Bestrahlung auf eukaryote...
ADP sensitizes ZL55 cells to the activity of cisplatin
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Full Text...
Epidermal Growth Factor Protects Squamous Cell Carcinoma against Cisplatin-Induced Cytotoxicity through Increased Interleukin...
Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. - Semantic Scholar
The mechanisms underlying the proapoptotic effect of the chemotherapeutic agent, cisplatin, | Pharmacokinetic interaction of...
Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8
Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and...
DBL CISPLATIN INJECTION (cisplatin injection) | Pfizer Medical Information - Australia
Aging | Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small...
RePub, Erasmus University Repository:
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced...
Peripheral neuroglial death induced by cisplatin administration in newborn rats<...
Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
High-Dose Cisplatin Therapy for Cancer for the Ovary: Neurotoxicity | Annals of Internal Medicine | American College of...
Cisplatin Chemoradiation Course in Locally Advanced Head and Neck Cancer - The ASCO Post
Aging | MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133|sup|+|/sup| hepatocellular carcinoma cells by targeting...
Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro
Cancers | Free Full-Text | Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side...
Use of organotypic cultures of Cortis organ to study the protective effects of antioxidant molecules on cisplatin-induced...
Effect of miR-29 on cisplatin sensitivity of ovarian cancer cells<...
Evaluation of mitochondria in mouse oocytes following cisplatin exposure - DOAJ
The effects of cisplatin on developing nociceptive pathways - Nottingham ePrints
Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models<...
Plus it
Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab...
Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer
JCI -
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
JCI -
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of...
IL-10 from dendritic cells but not from T regulatory cells protects against cisplatin-induced nephrotoxicity<...
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer | Oncogene
Erythropoietin enhances recovery after cisplatin‐induced acute renal failure in the rat : Nephrology Dialysis Transplantation -...
Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma<...
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines<...
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-...
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer<...
Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors<...
SENSITIZATION OF HUMAN OSTEOSARCOMA CELL LINE 143B WITH CALCITRIOL FOR CISPLATIN THERAPY
NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner<...
Addition of Induction Gemcitabine/Cisplatin to Chemoradiotherapy in Nasopharyngeal Carcinoma - The ASCO Post
Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity<...
Evaluation of the effects of taurine on cisplatin-induced kidney injury and oxidative stress in male rats - Physiology and...
Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action<...
Protective effects of apocynin on cisplatin-induced ototoxicity in an auditory cell line and in zebrafish<...
Prophylactic effect of diacerein against cisplatin-induced nephrotoxicity in rats<...
Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity | IRIS...
Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway<...
Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle...
Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro |...
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with...
Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer : Medical resource use, costs, and...
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for...
Cis-diamminedichloroplatinum | definition of Cis-diamminedichloroplatinum by Medical dictionary
Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin<...
Cisplatin induces protective autophagy through activation of BECN1 in | DDDT
Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute...
The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. - The...
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing...
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two...
SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study...
Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small...
Induction Chemotherapy with Cisplatin and 5-Fluorouracil in Advanced Head and Neck Cancers: A Short Term Response Evaluation ...
The roles of copper transporters in cisplatin resistance<...
Determination of cisplatin, transplatin and amminetri-chloroplatinate by high performance liquid chromatography in one run...
Effects of genistein on anti-tumor activity of cisplatin in human cervical cancer cell lines
Plus it
Cisplatin
... was the first to be developed. In 1983 pediatric oncologist Roger Packer began incorporating cisplatin into adjuvant ... "Cisplatin". Drug Information Portal. U.S. National Library of Medicine. IARC Monograph: "Cisplatin" Portal: Medicine (Articles ... It is suggested that an antibody reacting with a cisplatin-red-cell membrane is responsible for hemolysis. Cisplatin can ... adducts formed by cisplatin in abundance. Cisplatin is the square planar coordination complex cis-[Pt(NH3)2Cl2].: 286-8 : 689 ...
Inorganic chemistry
Examples: iron pentacarbonyl, titanium tetrachloride, cisplatin Usually, organometallic compounds are considered to contain the ... Cisplatin). The field, which incorporates many aspects of biochemistry, includes many kinds of compounds, e.g., the phosphates ...
Crosslinking of DNA
When cisplatin forms interstrand crosslinks (5'-GC), there is a severe distortion to the DNA helix due to a shortened distance ... "Cisplatin". National Cancer Institute. 2007-03-02. Retrieved 2017-10-09. Cimino, G. D.; Gamper, H. B.; Isaacs, S. T.; Hearst, J ... When cisplatin generates DNA crosslinks, it more frequently forms 1,2-intrastrand crosslinks (5'-GG), but also forms 1,3- ... Cisplatin (cis-diamminedichloroplatinum(II)) and its derivatives mostly act on adjacent guanines at their N7 positions. The ...
Thiopurine methyltransferase
"Cisplatin". Science & Research (Drugs). United States Food and Drug Administration. Reuther LO, Vainer B, Sonne J, Larsen NE ( ... Genetic variants of TPMT have also been associated with cisplatin-induced ototoxicity in children. TPMT is now listed as a ... "Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy". Nat. Genet. ... pharmacogenomic biomarker for adverse drug reactions to cisplatin by the FDA. Cancer pharmacogenomics GRCh38: Ensembl release ...
Kidney disease
Several chemotherapeutic agents, for example Cisplatin, are associated with acute and chronic kidney injuries. Newer agents ... Cisplatin nephrotoxicity. In: UpToDate, Palevsky PM (Ed), UpToDate, Waltham, MA, 2013. http://www.uptodate.com/contents/ ... cisplatin-nephrotoxicity Robinson, Emily S.; Khankin, Eliyahu V.; Karumanchi, S. Ananth; Humphreys, Benjamin D. (1 November ...
Carboplatin
Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some results show that cisplatin and carboplatin ... or the like-cisplatin hypothesis. Activation, or the unlike-cisplatin hypothesis. The former is more accepted owing to the ... It may be used for some types of testicular cancer but cisplatin is generally more effective. It has also been used to treat ... Relative to cisplatin, the greatest benefit of carboplatin is its reduced side effects, particularly the elimination of ...
Undifferentiated pleomorphic sarcoma
... and cisplatin. These treatment regimens have been reported to lower local recurrence rates, prolong disease-free survival rates ... plus dacarbazine or cisplatin; cyclophosphamide, doxorubicin, plus dacarbazine; high dose methotrexate; or etoposide, ...
Transmembrane Protein 205
TMEM205 has been shown to be involved in Cisplatin resistance. Cisplatin is a chemotherapeutic drug that is commonly used to ... In addition to being involved in Cisplatin resistance there is growing evidence that the protein is also involved in the ... Shen DW, Gottesman MM (March 2012). "RAB8 enhances TMEM205-mediated cisplatin resistance". Pharmaceutical Research. 29 (3): 643 ... is associated with cisplatin resistance". Journal of Cellular Physiology. 225 (3): 822-8. doi:10.1002/jcp.22287. PMC 2971691. ...
Kurnakov test
The test is still used to assay samples of the drug cisplatin, but it is mainly of pedagogical interest, as it illustrates the ... The Kurnakov test is sometimes used to detect transplatin in samples of the drug cisplatin. In hot aqueous solution, the cis- ... "The Discovery and Development of Cisplatin". Journal of Chemical Education. 83 (5): 728-773. Bibcode:2006JChEd..83..728A. doi: ...
Chemical synthesis
Alderden, Rebecca A.; Hall, Matthew D.; Hambley, Trevor W. (1 May 2006). "The Discovery and Development of Cisplatin". J. Chem ... An illustrative example is the preparation of the anti-cancer drug cisplatin from potassium tetrachloroplatinate. Beilstein ...
Platinum
Cisplatin, or cis-diamminedichloroplatinum(II) is the first of a series of square planar platinum(II)-containing chemotherapy ... Side effects of cisplatin include nausea and vomiting, hair loss, tinnitus, hearing loss, and nephrotoxicity.) Organoplatinum ... The hexachloroplatinate ion The anion of Zeise's salt Dichloro(cycloocta-1,5-diene)platinum(II) Cisplatin Archaeologists have ... Riddell, Imogen A.; Lippard, Stephen J. (2018). "Cisplatin and Oxaliplatin:Our Current Understanding of Their Actions". In ...
Small-cell carcinoma
Cisplatin and etoposide, Carboplatin and etoposide. The drug paclitaxel may be useful in the treatment of cisplatin-resistant ... About 68.1% of cisplatin-resistant cells appear to be sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells to ... In Japan, first-line treatment is shifting to irinotecan and cisplatin. When the primary site is in the skin, it is referred to ... In cases of LS-SCLC, combination chemotherapy (usually cisplatin or carboplatin plus etoposide) is administered together with ...
Ototoxic medication
Such agents include cisplatin and bleomycin. Cisplatin is known as a platinum coordination complex. Carboplatin and oxaliplatin ... Cisplatin and other platinum coordination complexes work by reacting with various sites on DNA in mainly cancer cells in order ... The mechanism of cisplatin in inducing ototoxicity is believed to involve the accumulation of reactive oxygen species, which ... The use of D-methionine to protect against hearing loss induced by drugs like cisplatin and aminoglycosides is preliminarily ...
CLPTM1L
Cleft lip and palate transmembrane protein 1-like protein (CLPTM1-like protein), also known as cisplatin resistance-related ... CRR9p is associated with cisplatin-induced apoptosis. CLPTM1L, which lies within a cancer susceptibility locus on chromosome 5 ...
Deaths in August 2009
Barnett Rosenberg, 82, American chemist, discovered cisplatin. Raul Solnado, 79, Portuguese actor and comedian, cardiovascular ...
Deborah Zamble
Zamble, Deborah B.; Mu, David; Reardon, Joyce T.; Sancar, Aziz; Lippard, Stephen J. (1996-01-01). "Repair of Cisplatin−DNA ... Lippard on cisplatin, an anti-cancer drug. Her research considered the role of p53 in the cellular response to the drug. Zamble ... "Cisplatin and DNA repair in cancer chemotherapy". Trends in Biochemical Sciences. 20 (10): 435-439. doi:10.1016/S0968-0004(00) ... "HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision ...
Amikacin
... and cisplatin, which is used in chemotherapy. Amikacin should not be used with neuromuscular blocking agents, as they can ...
Martin Barratt
"Partial reversibility of cisplatin nephrotoxicity in children". The Journal of Pediatrics. 118 (4): 531-534. doi:10.1016/S0022- ...
Platinum-based antineoplastic
Cisplatin was the first to be developed. Cisplatin is particularly effective against testicular cancer; the cure rate was ... In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been ... As studied mainly on cisplatin, but presumably for other members as well, platinum-based antineoplastic agents cause ... Rudd GN, Hartley JA, Souhami RL (1995). "Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood ...
Metallothionein
Basu A, Krishnamurthy S (August 2010). "Cellular responses to Cisplatin-induced DNA damage". Journal of Nucleic Acids. 2010: 1- ...
LUC7L3
2003). "Effect of cisplatin treatment on speckled distribution of a serine/arginine-rich nuclear protein CROP/Luc7A". Biochem. ... "Entrez Gene: CROP cisplatin resistance-associated overexpressed protein". Human LUC7L3 genome location and LUC7L3 gene details ... LUC7 like 3 pre-mRNA splicing factor (LUC7L3), also known as Cisplatin resistance-associated overexpressed protein, or CROP, is ... This gene encodes a cisplatin resistance-associated overexpressed protein (CROP). The N-terminal half of the CROP contains ...
Chemotherapy
Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and ... Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin. On the other hand, therapies ... October 2014). "Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC". Cancer Biology & Therapy. 15 (10): ... Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (November 2009). "Cisplatin ototoxicity and protection: clinical and experimental ...
Hearing loss
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (November 2009). "Cisplatin ototoxicity and protection: clinical and experimental ... and platinum based chemotherapeutics such as cisplatin and carboplatin. In addition to medications, hearing loss can also ...
Antineoplastic resistance
Cisplatin resistance occurs when cancer cells develop an enhanced ability to reverse such damage by removing the cisplatin from ... The cisplatin-resistant cells upregulate expression of the excision repair cross-complementing (ERCC1) gene and protein. Some ... In ovarian cancer, the ATP7B gene encodes for a copper efflux transporter, found to be upregulated in cisplatin-resistant cell ... Platinum-based chemotherapies, such as cisplatin, target tumour cells by cross-linking their DNA strands, causing mutation and ...
Ovarian germ cell tumors
The major elements are cisplatin, carboplatin, and oxaliplatin. It has been reported with full recovery among early-stage ... It is known as the hyperthermic intraperitoneal chemotherapy (HIPEC), containing docetaxel, and cisplatin. Given the drug is ... and cisplatin, also known as the BEP treatment. Patients should be issued with 3-4 cycles of BEP to ensure full salvage. ... which consists of cisplatin, ifosfamide and paclitaxel. Yet, it is likely that OGCT survivors after BEP therapy will have ...
Urethral cancer
Commonly used drugs include cisplatin, vincristine, and methotrexate.[clarification needed] Side effects include anemia ( ...
Mesothelioma
July 2003). "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant ... Cisplatin and pemetrexed together give patients a median survival of 12.1 months. Cisplatin in combination with raltitrexed has ... albeit with similar survival figures to patients receiving cisplatin. Cisplatin in combination with premetrexed disodium, folic ... For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response ...
Causes of hearing loss
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (November 2009). "Cisplatin ototoxicity and protection: clinical and experimental ... and platinum based chemotherapeutics such as cisplatin and carboplatin. In 2007, the U.S. Food and Drug Administration (FDA) ...
RNF113A
"Investigation into ubiquitin signalling in response to cisplatin". Discovery Research Portal. University of Dundee. Retrieved 2 ... predicted to be a part of the ubiquitin ligase family and involved with DNA repair mechanisms after treatment with cisplatin, a ...
Richard D. Simons
Cisplatin ("Platinol") was given instead of carboplatin ("Paraplatin"). He resided in Rome, New York with his second wife, ...
Cisplatin | Cancer information | Cancer Research UK
Cisplatin is a type of chemotherapy. It is a treatment for a number of different types of cancer. Find out about how you have ... Cisplatin. Cisplatin is a chemotherapy drug. You might have it as a treatment for a number of different types of cancer. ... How does cisplatin work?. Cisplatin is a type of chemotherapy. It destroys quickly dividing cells, such as cancer cells. ... How often do you have cisplatin?. You usually have cisplatin as cycles of treatment. Each cycle varies depending on what type ...
Cisplatin Injection: MedlinePlus Drug Information
Cisplatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Cisplatin may cause severe allergic reactions, especially if you have received more than one dose of cisplatin injection. If ... Before taking cisplatin,. *tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any ... If you become pregnant while receiving cisplatin, call your doctor. Cisplatin may harm the fetus. ...
Weekly Cisplatin New Standard in Postop Head and Neck Cancer
... weekly cisplatin plus radiotherapy has been shown to be not only less toxic than dosing once every three weeks but also ... For Saba, the take-home message of the trial is that weekly cisplatin "is now, finally, an accepted standard of care in the ... For the first time, weekly cisplatin plus radiotherapy (CDDP+RT) has been shown to be not only less toxic than dosing once ... Cite this: Weekly Cisplatin New Standard in Postop Head and Neck Cancer - Medscape - Jun 10, 2020. ...
Browsing by Subject "Cisplatin"
cisplatin Uses, Side Effects, Dosage & Interactions
Drug Information on cisplatin includes side effects, uses, drug interactions, dosage, drug pictures, overdose symptoms, and ... What is cisplatin (Platinol, Platinol (Restricted Access), Platinol-AQ)?. *What are the possible side effects of cisplatin ( ... You should not breastfeed while using cisplatin.. How is cisplatin given (Platinol, Platinol (Restricted Access), Platinol-AQ)? ... Nervous system problems may occur up to several weeks after you receive cisplatin, and these effects may not be reversible. ...
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT - Full Text View - ClinicalTrials.gov
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT. The safety and scientific validity of this study is the responsibility ... Drug Information available for: Cisplatin Gemcitabine Gemcitabine hydrochloride Gefitinib Genetic and Rare Diseases Information ... Cisplatin. Gefitinib. Antineoplastic Agents. Antimetabolites, Antineoplastic. Antimetabolites. Molecular Mechanisms of ... An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced ...
Systemic application of honokiol prevents cisplatin ototoxicity without compromising its antitumor effect
... no drug or FDA approved treatment is currently available to prevent cisplatin … ... Cisplatin is a potent drug used in about 40% of cancer treatment but also leads to severe deafness in 60-80% of the cases. ... Cisplatin is a potent drug used in about 40% of cancer treatment but also leads to severe deafness in 60-80% of the cases. ... Systemic application of honokiol prevents cisplatin ototoxicity without compromising its antitumor effect Am J Cancer Res. 2020 ...
The Preventive Effect of Oxytocin to Cisplatin-Induced Neurotoxicity: An Experimental Rat Model
Thirty-six rats were administered intraperitoneally (i.p.) single dose cisplatin 10 mg/kg and divided in to 3 groups. ... This study was conducted to investigate the preventive effect of oxytocin (OT) on cisplatin-induced neurotoxicity in rats. ... We suggest that oxytocin may have beneficial effects against cisplatin-induced neurotoxicity. ... nontreated cisplatin-injected rats showed significantly higher TNF-,i,α,/i, and MDA levels and lower GSH level than ...
Peripheral sensory neuropathy and cisplatin chemotherapy | Neurology
JCI -
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin...
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor ... Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor ... 0.001 versus cisplatin; 2-way ANOVA (. n. = 5/group). (. B. and C. ) mRNA levels of Il1b. (. B. ) and Ccl2. (. C. ) in DRGs 8 ... 0.01 versus cisplatin; 2-way ANOVA (. n. = 5/group). (. D. -. G. ) Time-course evaluation of mechanical sensitivity in mice ...
Platinol (cisplatin) | Mesothelioma Treatment, Benefits, Side Effects
... cisplatin) is a platinum-based chemotherapy drug often used in combination to treat a variety of cancers, including ... Platinol (cisplatin) Rheumatrex (methotrexate) Sutent (sunitinib) Taxol (paclitaxel) Medical Marijuana Care Providers Clinical ... Recent Studies Using Cisplatin. Cisplatin has been in use for decades, but researchers continue to use it in studies as a ... What Is Cisplatin?. Cisplatin is a platinum-containing chemotherapy drug that specifically attacks fast-growing cells in the ...
TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected...
Seventeen biopsies of osteosarcoma patients receiving primary metotrexate, cisplatin and adryamicin chemotherapy followed by ... L. Richter, M. Buzzi and C. Dantas-Barbosa, "TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and ... 2010) TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral ... TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected ...
Search of: mesothelioma AND tumor AND Cisplatin AND Cisplatin | Recruiting, Not yet recruiting, Available Studies | Last update...
Understanding cisplatin resistance using cellular models - DORAS
How then should cisplatin-resistant cancers be treated? Cisplatin-resistant cell lines are often more sensitive to another ... but not directly to cisplatin resistance. There are multiple resistance mechanisms induced by cisplatin treatment, even in the ... Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in ... Two models were developed from H69 SCLC cells, H69-CP and H69CIS200 using 100 ng/ml or 200 ng/ml cisplatin respectively. Both ...
Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study
... cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study ... Figure 3 Case 8. Computed tomography images before (A, C) and after (B, D) four courses of modified docetaxel, cisplatin and ... cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; ... cisplatin and capecitabine (DCX) (mDCX). The primary lesion (A, B), swollen lymph nodes along the common hepatic artery (#8) (C ...
Understanding Cisplatin Resistance Mediated by a Copper Efflux Protein - Penn State
Understanding Cisplatin Resistance Mediated by a Copper Efflux Protein. *Boal, Amie Kathleen (PI) ... Preliminary data indicate that cisplatin can directly bind these proteins, all of which share a common fold and bind Cu(I) via ... DESCRIPTION (provided by applicant): Cisplatin is a widely used anticancer drug but its efficacy is limited due to intrinsic ... The proposed study will examine the interaction between cisplatin and regulatory copper binding domains (MBDs) from the ...
NIH Researchers Find Link Between Cisplatin Build-up and Hearing Loss | The Hearing Review
Using a sensitive technique to measure and map cisplatin in mouse and human ear tissues researchers found that forms of ... By looking at inner ear tissue of mice after the first, second, and third cisplatin treatment, researchers saw that cisplatin ... NIH Researchers Find Link Between Cisplatin Build-up and Hearing Loss. Dec 19, 2017 , Research , 0 , ... The NIH team pursued a new angle on the problem: What if the inner ear is not able to get rid of cisplatin, and cells in the ...
Patient information - Lung cancer adjuvant - Cisplatin and vinorelbine | eviQ
This document is a guide only and cannot cover every possible situation. The health professionals caring for you should always consider your individual situation when making decisions about your care. Contact your cancer clinic staff or doctor if you have any questions or concerns about your treatment, or you are having problems coping with side effects. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use of this document is subject to eviQs disclaimer available at www.eviQ.org.au. ...
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity : Sussex Research Online
Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment ... the AGs and cisplatin. ORC-13661 also prevents both hearing loss in a dose-dependent manner in rats treated with amikacin and ... ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. JCI Insight, 4 (15). pp. 1-19. ISSN 2379- ... that it may reduce the toxicity of AGs by directly competing for entry at the level of the MET channel and of cisplatin by a ...
The pharmacogenomics of cisplatin-induced hearing loss - UBC Library Open Collections
The pharmacogenomics of cisplatin-induced hearing loss Pussegoda, Kusala Abstract. Cisplatin is a widely used chemotherapeutic ... Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumours. A serious complication of cisplatin ... A serious complication of cisplatin treatment is permanent hearing loss. The study hypothesis is that genetic variants in genes ... These findings have the potential to influence treatment modifications for cisplatin therapy and may improve safety in children ...
Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant...
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural ... Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265-7279. 2003. View Article : ... Chen H, Landen CN, Li Y, Alvarez RD and Tollefsbol TO: Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells ... Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; CDDP, cis-dichlorodiammineplatinum (cisplatin); PARP, poly(ADP- ...
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,...
... compared to methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) for locally advanced or metastatic transitional cell ... of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).. PATIENTS ... Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, ... Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer December 12, 2018 PURPOSE: To compare long-term survival in ...
Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma
2012) Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally ... Background: Methotrexate, vinblastine, doxorubicin, and cisplatin regimen, and gemcitabine and cisplatin regimen are widely ... received another cisplatin-based regimen (e.g., a combination regimen with ifosfamide, 5-fluorouracil, etoposide, and cisplatin ... They received intravenous paclitaxel (60 mg/m2) and gemcitabine (1000 mg/m2) on days 1 and 8, and cisplatin (70 mg/m2) on day 2 ...
Neoadjuvant Atezolizumab in Combination with Cisplatin/Pemetrexed and as Maintenance for Resectable Pleural Mesothelioma Meets...
DENVER-September 12, 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT)-Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed ... "Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety ... Patients received four cycles of neoadjuvant cisplatin and pemetrexed plus atezolizumab (CPA), resection, then radiation (EPP ... Neoadjuvant Atezolizumab in Combination with Cisplatin/Pemetrexed and as Maintenance for Resectable Pleural Mesothelioma Meets ...
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed,...
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed ... and cisplatin (GC) versus those treated with gemcitabine, cisplatin, and nab-Paclitaxel (GCN). SECONDARY OBJECTIVES: I. To ... It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating ... ARM II: Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses ...
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy | BMC Cancer | Full Text
We established an in vitro approach wherein ovarian cancer cells with various sensitivities to cisplatin or paclitaxel were ... Four days after treatment the lethality of cisplatin-paclitaxel was evidenced by reduced number of cells, increased hypodiploid ... Seven days after receiving cisplatin-paclitaxel, cultures showed signs of relapse with escaping colonies that repopulated the ... Conversely, cultures exposed to cisplatin-paclitaxel followed by mifepristone not only did not display signs of repopulation ...
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors | Academic Commons
In addition, we show that the acquired cisplatin resistance in vitro alters the expression of specific genes and the highly ... We hypothesize that these epigenetic alterations affecting MGMT play a major role in the exquisite sensitivity to cisplatin, ... We studied epigenetic changes in relation to cisplatin response by examining promoter hypermethylation in a cohort of resistant ... These results also implicate defects in epigenetic pathways that regulate gene transcription in cisplatin resistant GCT. ...
庄子 聡 (Satoshi Shoii) - Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk...
All enrolled patients received cisplatin with hydration, magnesium supplementation and mannitol. Cisplatin-induced AKI was ... Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC cancer ... BACKGROUND: Nephrotoxicity is the major side effect that limits the dose of cisplatin that can be safely administered, and it ... CONCLUSIONS: We should consider avoiding administration of cisplatin to patients with CKD risk factors, particularly cardiac ...
Developing cisplatin-inducedNephrotoxicityCarboplatinAssociated with cisplatin-inducedDoxorubicinDoses of cisplatinOtotoxicityEfficacyWeekly cisplatinRisk of cisplatin-inducedPreventing the cisplatin-inducedTreatmentDoseCDDPSide effects of cisplatinPatients treated with cisplatinAnticancerTreated with gemcitabineChemotherapeutic agent cisplatinCytotoxicityRadiotherapyEtoposideResistanceCombinationAdministration of cisplatinPaclitaxelPleural mesotheliomaSignificantlyClinicalFree cisplatinReceive cisplatinCyclophosphamideBladder cancerTumorCancerAdjuvantPlatinol-AQPeripheralRatsVitroRadiationSurvivalOxidativeTumorsMetastaticMETHODSInhibitionDocetaxelOsteosarcoma patientsKidney damage
Developing cisplatin-induced2
- Our findings suggest that if we can prevent cisplatin from entering the stria vascularis in the inner ear during treatment, we may be able to protect cancer patients from developing cisplatin-induced hearing loss," said Cunningham. (hearingreview.com)
- Patients with more risk factors for CKD tended to have a greater risk of developing cisplatin-induced AKI. (researchmap.jp)
Nephrotoxicity16
- Autotoxicity, neurotoxicity, and nephrotoxicity are the dose-limiting side effects of cisplatin [ 2 ]. (hindawi.com)
- In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. (jci.org)
- Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. (researchmap.jp)
- BACKGROUND: Nephrotoxicity is the major side effect that limits the dose of cisplatin that can be safely administered, and it is a clinical problem in cancer patients who received cisplatin combination chemotherapy. (researchmap.jp)
- Univariate analysis revealed that cardiac disease and use of non-steroidal anti-inflammatory drugs (NSAIDs) were associated with cisplatin-induced nephrotoxicity (odds ratios [OR] 6 and 3.56, 95% confidence intervals [CI] 1.21-29.87 and 1.11-11.39, p = 0.04 and p = 0.04, respectively). (researchmap.jp)
- Multivariate analysis revealed that cisplatin nephrotoxicity occurred significantly more often in patients with both risk factors (OR 13.64, 95% CI 1.11-326.83, p = 0.04). (researchmap.jp)
- A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT)" by Anshika Jain, Ryan Huang et al. (uwo.ca)
- The A Canadian study of Cisplatin mEtabolomics and NephroToxicity (ACCENT) team was established to harness the power of metabolomics to identify novel biomarkers that predict risk and discriminate for presence of cisplatin nephrotoxicity, so that early intervention strategies to mitigate onset and severity of AKI can be implemented. (uwo.ca)
- Objective: Describe the design and methods of the ACCENT study which aims to identify and validate metabolomic profiles in urine and serum associated with risk for cisplatin-mediated nephrotoxicity in children and adults. (uwo.ca)
- Cisplatin is a widely used chemotherapeutic medication the clinical usage of which is bound by the advancement of dose-dependent nephrotoxicity. (bioinf.org)
- These outcomes may have essential medical implications for preventing the cisplatin-induced nephrotoxicity with PARP inhibitors, IKBA which currently show powerful anticancer actions in medical tests and synergistic anticancer impact with cisplatin in multiple experimental paradigms. (bioinf.org)
- The purpose of this study was to evaluate the role of LA in a model of cisplatin-induced nephrotoxicity. (uab.edu)
- We demonstrated that use of MAZ51, a selective VEGFR3 inhibitor, caused significantly worse structural and functional kidney damage in cisplatin nephrotoxicity. (uab.edu)
- Cisplatin nephrotoxicity is associated with vascular congestion due to endothelial dysfunction. (uab.edu)
- Our findings identify a protective role for de novo LA in cisplatin nephrotoxicity and provide a rationale for the development of therapeutic approaches targeting LA. Our study also suggests off-target effects of MAZ51 on the vasculature in the setting of cisplatin nephrotoxicity. (uab.edu)
- Objective: The current study was designed to evaluate the protective effect of standardized hydroalcoholic extract of Plumeria rubra (HAEPR) against cisplatin-induced nephrotoxicity in Wistar rats. (who.int)
Carboplatin4
- tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any other medications, or any of the ingredients in cisplatin injection. (medlineplus.gov)
- Thus, cisplatin and paclitaxel, and later carboplatin plus paclitaxel, have been broadly accepted as first-line chemotherapy for advanced epithelial ovarian cancer. (biomedcentral.com)
- Previous results suggested that a combination of HSP90 inhibitors and the cisplatin analogue carboplatin resulted in a strong antitumour synergy in ovarian cancer cells. (uni-goettingen.de)
- Patients were treated on sequential dose escalation cohorts of tarextumab (5-15mg/kg) administered every three weeks with etoposide and either cisplatin or carboplatin (platinum-based therapy). (globenewswire.com)
Associated with cisplatin-induced3
- Recently, our group identified several predictive genetic variants that were highly associated with cisplatin-induced hearing loss in children. (ubc.ca)
- We identified novel variants in ABCB5 (rs10950831, P=1.06×10⁻⁶, OR 2.0) and DPYD (rs6667550, P=0.0047, OR 1.9) that were significantly associated with cisplatin-induced hearing loss. (ubc.ca)
- issue 16, pages 1725-1739) discuss the involvement of TLR2 and TLR4 in autophagy associated with cisplatin-induced acute kidney injury. (portlandpress.com)
Doxorubicin7
- To combat this resistance, cisplatin is typically combined with doxorubicin, pemetrexed , and gemcitabine. (mesothelioma.net)
- Combined with doxorubicin, cisplatin is often used for patients in advanced stages of mesothelioma. (mesothelioma.net)
- A combination of radical surgery, radiation, and chemotherapy with cisplatin, doxorubicin, and cyclophosphamide significantly improved survival times for patients. (mesothelioma.net)
- PURPOSE: To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). (urotoday.com)
- Background: Methotrexate, vinblastine, doxorubicin, and cisplatin regimen, and gemcitabine and cisplatin regimen are widely used for advanced or metastatic urothelial carcinomas (UCs). (scirp.org)
- In patients with advanced or metastatic urothelial cancers (UCs), combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) was frequently used as standard treatment [1,2]. (scirp.org)
- The combination of methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) is the standard treatment for metastatic bladder cancer. (medscape.com)
Doses of cisplatin4
- A series of resistant models were developed from CCRF-CEM leukaemia cells with increasing doses of cisplatin from 100 ng/ml. (dcu.ie)
- We established an in vitro approach wherein ovarian cancer cells with various sensitivities to cisplatin or paclitaxel were exposed to a round of lethal doses of cisplatin for 1 h plus paclitaxel for 3 h. (biomedcentral.com)
- Cytostatic concentrations of mifepristone after exposure to lethal doses of cisplatin and paclitaxel in combination blocks repopulation of remnant cells surviving and escaping the cytotoxic drugs. (biomedcentral.com)
- The first two studies used the Src inhibitor as a cotreatment with single doses of cisplatin in Fischer 344/NHsd rats and nude rats, respectively. (cdc.gov)
Ototoxicity11
- Although the mechanism is known to be related to the accumulation of reactive oxygen species (ROS), no drug or FDA approved treatment is currently available to prevent cisplatin ototoxicity. (nih.gov)
- Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity. (bvsalud.org)
- However, cisplatin -induced ototoxicity limits the utility of this agent in cancer patients , especially when dose escalations are needed. (bvsalud.org)
- Previous studies have demonstrated a role of CXC chemokines in cisplatin ototoxicity . (bvsalud.org)
- These results implicate the CXCL1 chemokine as an early player in cisplatin ototoxicity , possibly by initiating the immune cascade, and indicate that CXCR2 is a relevant target for treating cisplatin ototoxicity . (bvsalud.org)
- An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. (cdc.gov)
- Ototoxicity remains a major dose-limiting side effect of cisplatin. (cdc.gov)
- The current studies were carried out to evaluate the effectiveness of a novel Src-protein tyrosine kinase inhibitor in protecting the ear from cisplatin ototoxicity without compromising cisplatin's antitumor effects. (cdc.gov)
- Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. (chop.edu)
- The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. (chop.edu)
- The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. (chop.edu)
Efficacy5
- DESCRIPTION (provided by applicant): Cisplatin is a widely used anticancer drug but its efficacy is limited due to intrinsic and acquired cellular resistance. (elsevier.com)
- We examined the efficacy and safety of secondline paclitaxel, gemcitabine, and cisplatin (PCG) chemotherapy in Japanese patients. (scirp.org)
- We, therefore, investigated the efficacy and safety of PCG as second-line chemotherapy regimen after failure of cisplatin-based treatment. (scirp.org)
- We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcitabine as adjuvant treatment in patients with resected BTC. (biomedcentral.com)
- Results: The efficacy of HAEPR was compared with Cisplatin (CP) treated group. (who.int)
Weekly cisplatin2
- For the first time, weekly cisplatin plus radiotherapy (CDDP+RT) has been shown to be not only less toxic than dosing once every three weeks but also achieves better outcomes in patients with postoperative squamous cell carcinoma of the head and neck (SCCHN), say Japanese researchers. (medscape.com)
- For Saba, the take-home message of the trial is that weekly cisplatin "is now, finally, an accepted standard of care in the postoperative high-risk setting, which is a major change at this ASCO meeting. (medscape.com)
Risk of cisplatin-induced1
- Furthermore, this study demonstrates that predictive models can classify patients based on predicted risk of cisplatin-induced hearing loss. (ubc.ca)
Preventing the cisplatin-induced1
- As oxidative stress and inflammation play the major role in the pathogenesis of cisplatin-induced neurotoxicity and the antioxidant/anti-inflammatory effects of OT are well known, we hypothesized that OT may be beneficial in preventing the cisplatin-induced neurotoxicity. (hindawi.com)
Treatment52
- You usually have cisplatin as cycles of treatment. (cancerresearchuk.org)
- Your doctor will order certain tests before, during, and after your treatment to check your body's response to cisplatin. (medlineplus.gov)
- Cisplatin is used combination with other medications to treat cancer of the testicles that has not improved or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
- Cisplatin is used alone or in combination with other medications to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
- Cisplatin is a potent drug used in about 40% of cancer treatment but also leads to severe deafness in 60-80% of the cases. (nih.gov)
- Cisplatin ( cis -diamminedichloroplatinum) is the first antineoplastic agent which has been used in cancer treatment. (hindawi.com)
- Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. (jci.org)
- Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. (jci.org)
- B and C ) mRNA levels of Il1b ( B ) and Ccl2 ( C ) in DRGs 8 days after the start of cisplatin treatment. (jci.org)
- Cisplatin is a common treatment choice for mesothelioma, often used in combination with other drugs. (mesothelioma.net)
- Combining cisplatin with other medications has been a basic treatment approach for decades. (mesothelioma.net)
- Cisplatin resistance in these cells correlated with increases in the antioxidant glutathione, yet treatment with buthionine sulphoximine, an inhibitor of glutathione synthesis, had no effect on resistance, suggesting that the increase in glutathione was not directly involved in cisplatin resistance. (dcu.ie)
- There are multiple resistance mechanisms induced by cisplatin treatment, even in the same cell type. (dcu.ie)
- Cisplatin-resistant cell lines are often more sensitive to another chemotherapeutic drug paclitaxel (H69CIS200), or are able to be sensitised to cisplatin with paclitaxel pre-treatment (H69-CP). (dcu.ie)
- The understanding of this sensitisation by paclitaxel using cell models of cisplatin resistance will lead to improvements in the clinical treatment of cisplatin resistant tumours. (dcu.ie)
- The new findings help explain why cisplatin is so toxic to the inner ear, and why hearing loss gets worse after each treatment, can occur long after treatment, and is more severe in children than adults. (hearingreview.com)
- In most areas of the body, cisplatin is eliminated within days or weeks after treatment, but in the inner ear, the drug remains much longer. (hearingreview.com)
- By looking at inner ear tissue of mice after the first, second, and third cisplatin treatment, researchers saw that cisplatin remained in the mouse inner ear much longer than in most other body tissues, and that it builds up with each successive treatment. (hearingreview.com)
- They also studied inner ear tissue donated by deceased adult patients who had been treated with cisplatin, and observed that cisplatin is retained in the inner ear many months or years after treatment. (hearingreview.com)
- Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear. (sussex.ac.uk)
- Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumours. (ubc.ca)
- A serious complication of cisplatin treatment is permanent hearing loss. (ubc.ca)
- These findings have the potential to influence treatment modifications for cisplatin therapy and may improve safety in children. (ubc.ca)
- We administered PCG to 25 patients with advanced UC after failure of first-line cisplatin-based regimen between 2004 and 2010 at Saitama Red Cross Hospital, which is one of regional cancer treatment centers designnated by the Ministry of Health, Labour and Welfare of Japan since 2005 and is able to provide standard cancer care for regional patients. (scirp.org)
- In this work we questioned whether the synthetic steroid mifepristone, which as monotherapy inhibits the growth of ovarian cancer cells, is capable of preventing repopulation of ovarian cancer cells if given after a round of lethal cisplatin-paclitaxel combination treatment. (biomedcentral.com)
- Four days after treatment the lethality of cisplatin-paclitaxel was evidenced by reduced number of cells, increased hypodiploid DNA content, morphological features of apoptosis, DNA fragmentation, and cleavage of caspase-3, and of its downstream substrate PARP. (biomedcentral.com)
- Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. (columbia.edu)
- We also demonstrate that cisplatin treatment induce de novo promoter hypermethylation in vivo. (columbia.edu)
- In addition, we show that the acquired cisplatin resistance in vitro alters the expression of specific genes and the highly resistant cells fail to reactivate gene expression after treatment to demethylating and histone deacetylase inhibiting agents. (columbia.edu)
- Blood and urine will be collected at specified time points before and after cisplatin during the first infusion and an infusion later during cancer treatment. (uwo.ca)
- Here we found that in basal-like PDAC cells, the combination of HSP90 inhibition and cisplatin treatment resulted in a synergistic reduction of cell viability, increased DNA damage and chromosome fragmentation. (uni-goettingen.de)
- Our study suggests that PDAC cells show a distinct response towards cisplatin treatment and that combination of cisplatin with the HSP90 inhibitor onalespib is able to overcome cisplatin resistance in basal-like PDAC cells. (uni-goettingen.de)
- Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. (lamblawoffice.com)
- The current treatment of PC consists of perioperative systemic chemotherapy and cytoreductive surgery, followed by intra-abdominal flushing with solutions of chemotherapeutics such as cisplatin and oxaliplatin. (ugent.be)
- Purpose: Our previous study demonstrated the benefit of cumulative dose of cisplatin during the whole treatment on locally advanced nasopharyngeal carcinoma (NPC) treated with various chemotherapy strategies. (jcancer.org)
- The purpose of this study is to identify the subgroup of locally advanced NPC who benefits from higher dose of cisplatin, and to clarify whether cumulative dose of cisplatin during the whole treatment brings survival benefit to those treated with concurrent chemoradiotherapy (CCRT). (jcancer.org)
- Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. (elsevier.com)
- The treatment of cisplatin-resistant disease is challenging and prognosis remains poor. (elsevier.com)
- Here, we provide an overview of current and potential new treatment options including combination chemotherapy, high-dose chemotherapy and molecular targeted therapies, for patients with cisplatin-resistant ovarian germ cell tumors. (elsevier.com)
- In another group of tests, AIQ and PJ34 treatment began 12 and 24 h following the cisplatin. (bioinf.org)
- Gemcitabine plus cisplatin is now considered a first-line treatment for bladder cancer. (medscape.com)
- Gemcitabine is used in combination with cisplatin for the treatment of advanced or metastatic bladder cancer. (medscape.com)
- Cisplatin was considered the best treatment option before the advent of the antifolate agents, Dr. Berghmans commented. (medscape.com)
- In the second trial presented at a press conference by Dr. Berghmans, first-line treatment with raltitrexed plus cisplatin was associated with a progression-free survival of 5.3 months, compared with 4 months for treatment with cisplatin alone ( P = .06). (medscape.com)
- Cisplatin plus pemetrexed is the best treatment we've got for mesothelioma," Dr. Berghmans asserted. (medscape.com)
- One patient died due to infectious complications during treatment with cisplatin and gemcitabine. (biomedcentral.com)
- Cisplatin is chemotherapy used for solid tumor treatment like lung , bladder , head and neck , ovarian and testicular cancers . (bvsalud.org)
- KEMPINAS, W. G. Paternal treatment with cisplatin impairs reproduction of adult male offspring in rats. (bvsalud.org)
- Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. (chop.edu)
- Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. (chop.edu)
- The drug in question is cisplatin, widely used for cancer treatment for more than 40 years. (sunoforlife.com)
- Researchers also think that long term follow-up of those treated with cisplatin is necessary to see what effect aging has on hearing loss, meaning thorough hearing assessments are important before, during and after treatment. (sunoforlife.com)
Dose18
- Cisplatin may cause severe allergic reactions, especially if you have received more than one dose of cisplatin injection. (medlineplus.gov)
- A child treated with cisplatin may need a hearing test before receiving the first dose. (emedicinehealth.com)
- Peripheral neurotoxicity is a frequent dose-limiting side effect of the chemotherapeutic agent cisplatin. (hindawi.com)
- Thirty-six rats were administered intraperitoneally (i.p.) single dose cisplatin 10 mg/kg and divided in to 3 groups. (hindawi.com)
- Cisplatin-induced peripheral neuropathy is a frequent adverse effect leading to a dose reduction or the early cessation of chemotherapy, thereby potentially impacting patient survival [ 3 ]. (hindawi.com)
- Since cisplatin-induced neurotoxicity is the major dose-limiting adverse effect of cisplatin, there are numerous studies dealing with this issue [ 9 ]. (hindawi.com)
- Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? (jcancer.org)
- Ou X, Xu T, He X, Ying H, Hu C. Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? (jcancer.org)
- The median cumulative dose of cisplatin of 300mg/m 2 was chose to be the cutoff value of low and high dose subgroups. (jcancer.org)
- Cumulative dose of cisplatin were demonstrated an independent prognostic factors for DMFS (HR=0.524, 95% CI 0.340-0.806) and OS (HR=0.577, 95% CI 0.373-0.893) for the entire cohort upon MVA. (jcancer.org)
- Similarly, in the subgroup of T3-4N2-3, higher dose of cisplatin was associated with higher OS (80.3% vs. 52.3%, p=0.032). (jcancer.org)
- Cumulative dose of cisplatin was an independent prognostic factor for DMFS (HR=0.483, 95%CI 0.292-0.798) and OS (HR=0.429, 95%CI 0.258-0.715) for patients with T1-4N2-3 disease upon MVA. (jcancer.org)
- However, the benefit of higher dose of cisplatin was not observed in the subgroup of T3-4N0-1. (jcancer.org)
- For patients receiving CCRT (n=278), those treated with higher dose of cisplatin had a significantly higher DMFS (87.7% vs. 75.4%, p=0.004). (jcancer.org)
- Cumulative dose of cisplatin was associated with a lower risk of distant metastasis (HR=0.427, 95% CI 0.228-0.801) for patients treated with CCRT upon MVA. (jcancer.org)
- The third study was carried out in nude rats with implanted HT-29 tumors, and the Src inhibitor was administered as a cotreatment with a lower dose of cisplatin. (cdc.gov)
- In the third study, little hearing loss was induced because of the use of a lower dose of cisplatin. (cdc.gov)
- It was discovered that for every 100 mg/m 2 increase in cumulative dose of cisplatin, there was a 3.2 decibel (dB) impairment in age-adjusted overall hearing thresholds. (sunoforlife.com)
CDDP1
- Further, as experimental verification of microarray data, the cytotoxicity of the cisplatin (CDDP) was examined in hMT-3 and mock cells by MTT and clonogenic assays. (oncotarget.com)
Side effects of cisplatin2
- What are the side effects of cisplatin? (cancerresearchuk.org)
- What are the possible side effects of cisplatin (Platinol, Platinol (Restricted Access), Platinol-AQ)? (emedicinehealth.com)
Patients treated with cisplatin2
- The study hypothesis is that genetic variants in genes involved in drug metabolism and transport can contribute to increased susceptibility to hearing loss in pediatric oncology patients treated with cisplatin. (ubc.ca)
- METHODS: We retrospectively analyzed 84 patients treated with cisplatin combination chemotherapy for thoracic malignancies. (researchmap.jp)
Anticancer1
- PUBLIC HEALTH RELEVANCE: This project will result in molecular level characterization of the interaction between cisplatin, a widely prescribed anticancer drug, and copper transporters. (elsevier.com)
Treated with gemcitabine1
- PRIMARY OBJECTIVES: I. To compare overall survival (OS) in patients with untreated, advanced biliary cancers treated with gemcitabine hydrochloride (gemcitabine) and cisplatin (GC) versus those treated with gemcitabine, cisplatin, and nab-Paclitaxel (GCN). (clinicalconnection.com)
Chemotherapeutic agent cisplatin1
- We analysed the response of a panel of seven PDAC cell lines against the chemotherapeutic agent cisplatin, determining two clearly separated response categories, cisplatin-sensitive and resistant cells. (uni-goettingen.de)
Cytotoxicity3
- Oxidative stress, DNA damage, and inflammatory cytokines play major role in the mechanism of cisplatin-induced cytotoxicity [ 10 ]. (hindawi.com)
- Prepared DXA derivatives (M-w = 10-185 kDa) have been conjugated to cisplatin and the M-w of the carrier found to have a significant impact on cisplatin release rates, in vitro cytotoxicity, and migrastatic potential. (muni.cz)
- The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. (bvsalud.org)
Radiotherapy1
- You might have cisplatin on its own or in combination with other cancer drugs or radiotherapy. (cancerresearchuk.org)
Etoposide2
- The initial chemotherapy which consisted of four cycles of cisplatin and adriamycin alternative with ifosfamide and etoposide was provided. (cancerjournal.net)
- The survival with cisplatin-docexatel is better compared to cisplatin-etoposide, this applies to PFS as well. (ui.ac.id)
Resistance8
- Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts. (dcu.ie)
- This suggests that increases in glutathione may contribute to cross-resistance to other drugs and radiation, but not directly to cisplatin resistance. (dcu.ie)
- Recent studies indicate that copper homeostatic proteins, particularly copper transport pumps and chaperones, may mediate cisplatin resistance. (elsevier.com)
- Our findings suggest that promoter hypermethylation of RASSF1A and HIC1 genes play a role in resistance of GCT, while the transcriptional inactivation of MGMT by epigenetic alterations confer exquisite sensitivity to cisplatin. (columbia.edu)
- The cisplatin-resistant cells can be linked to the basal-like subtype, which is characterised by even higher aggressiveness, lower survival rate and chemo-resistance. (uni-goettingen.de)
- Cisplatin-resistant UC cell lines were generated to investigate underlying mechanisms and to develop new approaches for overcoming resistance. (maastrichtuniversity.nl)
- Interestingly, each cisplatin-resistant cell line contained an individual assortment of resistance mechanisms at multiple levels. (maastrichtuniversity.nl)
- Loss-of-function studies showed that CDC25A promoted cisplatin-resistance and paclitaxel-resistance and inhibited the drug-induced apoptosis in ovarian cancer MCS. (jcancer.org)
Combination10
- Cisplatin is also used alone or in combination with other medications to treat bladder cancer that can not be treated with surgery or radiation therapy alone. (medlineplus.gov)
- Clinical trials show that patients with mesothelioma live longer when given this combination than when receiving cisplatin alone, and the FDA approved it as a therapy for pleural mesothelioma in 2004. (mesothelioma.net)
- Cisplatin has also been tested in combination with the chemotherapy drug gemcitabine for mesothelioma patients. (mesothelioma.net)
- Combination chemotherapy with gemcitabine and cisplatin (GC) has been demonstrated to be equally effective and less toxic than M-VAC [3]. (scirp.org)
- Materials and Methods: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. (iiarjournals.org)
- Results: Necitumumab in combination with cisplatin/gemcitabine was particularly effective, although interestingly, the mechanisms underlying these benefits were model dependent. (iiarjournals.org)
- In the first, 250 patients were randomized to either a combination of cisplatin plus raltitrexed or to cisplatin alone. (medscape.com)
- Patients initially received gemcitabine 1000 mg/m 2 alone on days 1, 8 and 15 every 28-days for a total of six cycles (single agent cohort), and after protocol amendment a combination therapy with gemcitabine 1000 mg/m 2 and cisplatin 25 mg/m 2 on days 1 and 8 was administered every 21 days for a total of eight cycles (combined regimen cohort). (biomedcentral.com)
- The interim analysis met the predefined feasibility criteria and, from September 2010 on, the second group of 21 patients received the combination of cisplatin plus gemcitabine. (biomedcentral.com)
- Patients treated with the combination cisplatin-gemcitabine received an overall median RDI of 100% (IQR 50-100) for cisplatin and 100% (IQR 75-100) for gemcitabine respectively. (biomedcentral.com)
Administration of cisplatin2
- CONCLUSIONS: We should consider avoiding administration of cisplatin to patients with CKD risk factors, particularly cardiac disease and NSAID use. (researchmap.jp)
- Thus the researchers hope to use the results of the study to develop a way to protect hearing during the administration of cisplatin, rather than seek alternative treatments. (sunoforlife.com)
Paclitaxel8
- They received intravenous paclitaxel (60 mg/m 2 ) and gemcitabine (1000 mg/m 2 ) on days 1 and 8, and cisplatin (70 mg/m 2 ) on day 2 of every 21-day course. (scirp.org)
- developed a triplet first-line chemotherapy regimen of paclitaxel, gemcitabine, and cisplatin (PCG) and achieved an excellent response rate of 78% with median overall survival of 24 months [10]. (scirp.org)
- This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. (clinicalconnection.com)
- Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (clinicalconnection.com)
- It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers. (clinicalconnection.com)
- ARM I: Patients receive nab-paclitaxel intravenously (IV) over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. (clinicalconnection.com)
- Seven days after receiving cisplatin-paclitaxel, cultures showed signs of relapse with escaping colonies that repopulated the plate in a time-dependent manner. (biomedcentral.com)
- Conversely, cultures exposed to cisplatin-paclitaxel followed by mifepristone not only did not display signs of repopulation following initial chemotherapy, but they also had their clonogenic capacity drastically reduced when compared to cells repopulating after cisplatin-paclitaxel. (biomedcentral.com)
Pleural mesothelioma2
- Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer. (iaslc.org)
- We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. (lamblawoffice.com)
Significantly3
- Also, nontreated cisplatin-injected rats showed significantly higher TNF- α and MDA levels and lower GSH level than control group. (hindawi.com)
- The best conjugate was four times more effective against malignant prostatic cell lines than free cisplatin and significantly inhibited the ovarian cancer cell migration. (muni.cz)
- In the first two studies, cotreatment with the Src inhibitor reduced cisplatin-induced hearing loss significantly. (cdc.gov)
Clinical3
- We expect a paradigm shift in cisplatin chemotherapy based on the current study and future clinical trials, where honokiol is applied to reduce side effects including hearing loss. (nih.gov)
- L. Richter, M. Buzzi and C. Dantas-Barbosa, " TP 53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma," International Journal of Clinical Medicine , Vol. 4 No. 12A, 2013, pp. 44-50. (scirp.org)
- The identification of biomarkers predicting and detecting AKI in children and adults treated with cisplatin can greatly inform future clinical investigations and practices. (uwo.ca)
Free cisplatin2
- Injected Cis-pARG-HA NPs showed enhanced antitumor activity in a rat model of PC, compared to injection of the free cisplatin drug. (ugent.be)
- Therefore, this study demonstrates that nanoparticles carrying chemotherapeutics can be synergistically combined with the PIPAC technique for IP therapy of disseminated advanced ovarian tumors, while this synergistic effect was not observed for the administration of free cisplatin. (ugent.be)
Receive cisplatin4
- Nervous system problems may occur up to several weeks after you receive cisplatin, and these effects may not be reversible. (emedicinehealth.com)
- How often and how many times you receive cisplatin will depend on the type of cancer you have. (emedicinehealth.com)
- ARM II: Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. (clinicalconnection.com)
- Patients: Three hundred adults and 300 children planned to receive cisplatin therapy. (uwo.ca)
Cyclophosphamide1
- Cisplatin was adopted as primary chemotherapy schedule in the 1970s in association with cyclophosphamide [ 5 ]. (biomedcentral.com)
Bladder cancer1
- Cisplatin is used together with other cancer drugs to treat bladder cancer , testicular cancer , or ovarian cancer . (emedicinehealth.com)
Tumor4
- Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. (jci.org)
- In this study, we developed cisplatin-loaded polyarginine-hyaluronic acid nanoscale particles (Cis-pARG-HA NPs) with high colloidal stability, marked drug loading efficiency, unimpaired biological activity, and tumor-targeting ability. (ugent.be)
- Excitingly, PARP-1 in addition has been implicated in the chemoresistance of cancers cells to cisplatin [28, 29] and PARP inhibition displays synergistic chemosensitivity of triple-negative breasts cancer tumor cell lines to gemcitabine and cisplatin [30]. (bioinf.org)
- With this research we looked into the part of PARP-1 in cisplatin-induced kidney damage utilizing a well-established mouse style of cisplatin-induced nephropathy [6, 31C40] and the consequences of PARP inhibitors only or in conjunction with Riociguat cisplatin on viability of tumor cells. (bioinf.org)
Cancer15
- Cisplatin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
- Patients with advanced cancer, previously untreated, were given 60 mg/m 2 cisplatin plus 60 mg/m 2 adriamycin by monthly intravenous injections. (neurology.org)
- Because cisplatin targets fast-growing cells, it kills cancer cells and healthy cells that grow and divide rapidly. (mesothelioma.net)
- Cisplatin causes cancer cells to die by binding to and distorting DNA, triggering cell death. (mesothelioma.net)
- When first introduced in 1978, many considered cisplatin to be a cure for testicular cancer. (mesothelioma.net)
- Cisplatin is often combined with other drugs because, as a single agent, it may be effective for a limited period of time before the cancer becomes resistant to the drug. (mesothelioma.net)
- Cisplatin and similar platinum-based drugs are prescribed for an estimated 10 to 20 percent of all cancer patients, according to the NIH. (hearingreview.com)
- The NIH's National Cancer Institute supported research that led to the 1965 discovery of cisplatin and continued development leading to its success as an essential weapon in the battle against cancer. (hearingreview.com)
- Objective: To observe the effect of Curcumin in enhancing chemosensitivity of drug-resistant ovarian cancer cell line to cisplatin and investigate its mechanism. (cnki.com.cn)
- The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. (elsevier.com)
- It is believed that taking cisplatin with black cohosh can decrease the effectiveness of medicine for treating cancer. (parentinghealthybabies.com)
- Researchers examined the cumulative effects of cisplatin-based chemotherapy on the hearing of testicular cancer survivors through in-depth testing of their ability to hear sounds at different frequencies. (sunoforlife.com)
- Although it has been in use for more than four decades and is currently one of the most commonly used ototoxic medications used to treat cancer, information about cisplatin-related hearing loss in cancer survivors is limited at this point, as it is just beginning to be studied. (sunoforlife.com)
- Complicating matters is the fact that cisplatin, despite its association with hearing loss, has been extremely successful in treating testicular cancer in particular. (sunoforlife.com)
- Researchers also emphasize that although this particular study was focused on testicular cancer patients, the results could apply to anyone with an adult-onset cancer who is treated with cisplatin-based chemotherapy. (sunoforlife.com)
Adjuvant2
- Adjuvant chemotherapy with gemcitabine with or without cisplatin was well tolerated and resulted in promising survival of the patients. (biomedcentral.com)
- Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). (elsevier.com)
Platinol-AQ2
- What is the most important information I should know about cisplatin (Platinol, Platinol (Restricted Access), Platinol-AQ)? (emedicinehealth.com)
- What should I discuss with my healthcare provider before receiving cisplatin (Platinol, Platinol (Restricted Access), Platinol-AQ)? (emedicinehealth.com)
Peripheral1
- Boric acid improves the behavioral, electrophysiological and histological parameters of cisplatin-induced peripheral neuropathy in rats. (painresearchforum.org)
Rats4
- This study was conducted to investigate the preventive effect of oxytocin (OT) on cisplatin-induced neurotoxicity in rats. (hindawi.com)
- Adult male Wistar rats treated with cisplatin demonstrated significant hearing loss , assessed by auditory brainstem responses (ABRs), hair cell loss and loss of ribbon synapse . (bvsalud.org)
- Conclusion: Present investigation revealed that HAEPR resulted in attenuation of Cisplatin-induced renal damage in rats. (who.int)
- Three studies were carried out to determine whether this compound has otoprotective activity in rats treated with cisplatin. (cdc.gov)
Vitro1
- To assess the DNA-damaging effect of Auger e- released as close as possible to DNA without chemical damage, we radio-synthesized no-carrier-added (n.c.a.) [189, 191Pt]cisplatin and evaluated both its in vitro properties and DNA-damaging effect. (preprints.org)
Radiation1
- Patients received four cycles of neoadjuvant cisplatin and pemetrexed plus atezolizumab (CPA), resection, then radiation (EPP cases only), followed by one year of maintenance atezolizumab. (iaslc.org)
Survival3
- Chart review 3 months after cisplatin therapy end will be conducted to document kidney health and survival. (uwo.ca)
- October 7, 2008 (Berlin, Germany) - Investigators announced the findings from phase 3 studies, which found that cisplatin plus an antifolate - either pemetrexed or raltitrexed - increase survival in patients with mesothelioma nearly 3-fold. (medscape.com)
- Progression-free survival was 5.7 months in the cisplatin-plus-pemetrexed group and 3.9 months in the cisplatin-monotherapy group, a difference that was highly statistically significant ( P = .001), Dr. Berghmans said. (medscape.com)
Oxidative1
- On the other hand, pathophysiological mechanisms of cisplatin-induced neurotoxicity include oxidative damage, inflammation, mitochondrial dysfunction, DNA damage, and apoptotic cell death in the nervous system [ 11 , 12 ]. (hindawi.com)
Tumors2
- In treating mesothelioma, combinations are often recommended because cisplatin alone has a low response rate on mesothelioma tumors. (mesothelioma.net)
- Background: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. (uwo.ca)
Metastatic1
- Cisplatin-based chemotherapy is the standard of care in advanced and metastatic UC. (maastrichtuniversity.nl)
METHODS1
- Methods: Patients will be recruited before their first cycle of cisplatin. (uwo.ca)
Inhibition1
- Further, cisplatin efflux by export transporter seemed compromised upon HSP90 inhibition, as the platinum-DNA adduct formation was increased upon HSP90 inhibition. (uni-goettingen.de)
Docetaxel2
- Endoscopic findings (A, B) and computed tomography images (C, D) before (A, C) and after (B, D) seven courses of modified docetaxel, cisplatin and capecitabine (DCX) (mDCX). (wjgnet.com)
- Computed tomography images before (A, C) and after (B, D) four courses of modified docetaxel, cisplatin and capecitabine (DCX) (mDCX). (wjgnet.com)
Osteosarcoma patients1
- Seventeen biopsies of osteosarcoma patients receiving primary metotrexate, cisplatin and adryamicin chemotherapy followed by surgery were analyzed. (scirp.org)
Kidney damage1
- The platinum in cisplatin can cause kidney damage in some patients, especially those with previous kidney problems. (mesothelioma.net)